Volv Global at Tech Tour Growth Health 2026
Tech Tour Growth Health is one of Europe’s most established gatherings at the intersection of healthcare innova...
Volv Global personalises healthcare by providing insights on patients and diseases powered by data-driven AI and machine learning.
Our custom, proprietary, machine learning algorithms power a suite of services for pharmaceutical companies that reduces costs throughout the healthcare ecosystem and improves outcomes for those living with disease.
Stratify and triage patients for individualised and optimised treatment, saving time, cost and the emotional burden of incorrect diagnosis.
Characterise, segment and target patient cohorts to make clinical development and commercialisation more efficient and cost-effective.
Generate novel insights and new understanding of patient biomarkers, phenotypes, clinical features and endpoints.
Optimise resource allocation and reduce cost impact of incorrect or late diagnoses, while maximising quality of life and outcomes.
Volv Global helps you work smarter
Volv Global uses AI and population-scale data to generate knowledge and insights into difficult-to-diagnose diseases that others cannot match. Our clients can leverage these insights to enhance clinical development strategies, enrich disease understanding, and gain an edge over their rivals. Our insights help identify opportunities to rapidly develop diagnostic tools, reposition existing drugs that increase R&D viability, so our clients can target new markets, work smarter and drive profitability.
Volv Global, in numbers
Volv Global delivers high-value solutions at speed
De-risk clinical strategy & improve robustness of trial planning.
Generate meaningful and valuable real-world evidence.
Expand the boundaries of medical understanding with new RWD insights.
Launch strongly and extend the product lifecycle by finding more patients.
Driving Innovation in Rare Disease & Healthcare AI
At Volv Global, we combine advanced AI in healthcare with real-world data (RWD) to deliver transformative solutions for rare and difficult-to-diagnose disease patients. Our proprietary methodology for machine learning in healthcare technology enables:
– Detecting rare diseases faster and more accurately
– Generating real-world evidence (RWE) for clinical trials and regulatory submissions
– Optimising the patient journey with data-driven insights
– Reducing time and costs in drug development and market access
By partnering with Volv Global, pharmaceutical innovators, healthcare providers, and policymakers gain the tools to make smarter, faster, and more impactful decisions across the entire healthcare ecosystem.
Introducing inTrigue
With inTrigue, our flagship machine learning methodology, Volv Global transforms disease management and treatment at the individual patient level, along the patient journey and optimising patient outcomes.
Understanding patient phenomenology, across all diseases.
We ensure that all patients are offered the right treatment options and increase the pool of RWD on a disease.
We detect subtle patterns among biomarkers to predict disease incidence early, sometimes years ahead of time.
We model disease progression and are able to provide prognoses, instead of diagnoses.
We detect, cluster and differentiate sub-groups within a heterogenous patient cohort, to learn more about disease pathways.
The human story
Volv Global helps transform lives by giving pharmaceutical innovators powerful insights into difficult-to-diagnose diseases so they can develop effective tools and treatments. To the patient this might look like earlier diagnosis, a lifechanging drug or the opportunity to connect with a wider community for education and support as they navigate life with a rare disease.
Stay informed
Tech Tour Growth Health is one of Europe’s most established gatherings at the intersection of healthcare innova...
Volv Global is pleased to be participating in the Life Sciences Innovation & Investment Corridor between Lausanne...
The idea that an AI system could detect a disease that appears nowhere in a patient’s medical record sounds lik...
The ISPOR International Annual Conference 2026 brings together global leaders in health economics and outcomes resear...
By Léon Van Wouwe, Clinical Innovation Director, Volv Global Inflammatory Bowel Disease (IBD) management has evolved ...
Introduction Advocacy plays a critical role in accelerating progress in rare diseases. As technology advances, collab...
As our commemoration of Rare Disease Day 2026, we are pleased to present a guest article by Jessica Lynn at Rareative...
By Léon Van Wouwe, Clinical Innovation Director, Volv Global Introduction Earlier cancer detection remains one of the...
Finding the Patients We’re Missing Rare diseases often remain undiagnosed for years, leaving patients without t...
Introduction Volv Global participation in Faces of Industrial Research 2026 reflects its commitment to connecting sci...
In 2024, Sanofi – working in partnership with The BMJ – released the Rairity: Air Time For Rare Diseases podcast seri...
By Léon Van Wouwe, Clinical Innovation Director, Volv Global Introduction: COPD as a “Syndrome,” Not Just One ...
Go deeper
The ISPOR International Annual Conference 2026 brings together global leaders in health economics and outcomes resear...
By Léon Van Wouwe, Clinical Innovation Director, Volv Global Inflammatory Bowel Disease (IBD) management has evolved ...
Introduction Advocacy plays a critical role in accelerating progress in rare diseases. As technology advances, collab...
By Léon Van Wouwe, Clinical Innovation Director, Volv Global Introduction Earlier cancer detection remains one of the...
Finding the Patients We’re Missing Rare diseases often remain undiagnosed for years, leaving patients without t...
In 2024, Sanofi – working in partnership with The BMJ – released the Rairity: Air Time For Rare Diseases podcast seri...
By Léon Van Wouwe, Clinical Innovation Director, Volv Global Introduction: COPD as a “Syndrome,” Not Just One ...
By Léon Van Wouwe, Clinical Innovation Director, Volv Global Introduction: A Silent Disease Becoming a Public ...
By Léon Van Wouwe, Clinical Innovation Director, Volv Global Knowing When To Treat – AI for Transformation, Infection...
By Léon Van Wouwe, Clinical Innovation Director, Volv Global Early detection and personalised treatment in chronic ly...
By Léon Van Wouwe, Clinical Innovation Director, Volv Global A Hidden Cancer in Plain Sight Multiple myeloma (...
By Léon Van Wouwe, Clinical Innovation Director, Volv Global Introduction: The Urgency of Early Diagnosis in T...